Skip to main content
. Author manuscript; available in PMC: 2016 Feb 3.
Published in final edited form as: Cell Metab. 2015 Feb 3;21(2):183–194. doi: 10.1016/j.cmet.2015.01.005

Figure 3. Gene transfer of SERCA2a improves cardiac metabolism and energetic function in failing hearts.

Figure 3

A. The ratio of [PCr]-to-[ATP] and the levels of both PCr and ATP are lower in failing hearts compared to healthy hearts. The overexpression of SERCA2a in failing heart restores the [PCr]-to-[ATP] ratio toward normal (del Monte et al., 2001). B. Linear relationship between the oxygen cost of calcium handling (VO2) and left ventricular contractility (eEmax) in normal (■), failing (▲) and failing+SERCA2a (●) hearts. The slope of these linear relations represents the oxygen cost of left ventricular contractility. Treatment of failing hearts by SERCA2a gene therapy improves the energy cost of left ventricular contractility (Sakata et al., 2007).